Recent successes of cancer immunotherapy: a new dimension in personalized medicine?

Suppr

超能文献

作者信息

Caux Christophe, Zitvogel Laurence

出版信息

Target Oncol. 2012 Mar;7(1):1-2. doi: 10.1007/s11523-012-0211-3. Epub 2012 Feb 15.

DOI:10.1007/s11523-012-0211-3

PMID:22350488

Abstract

摘要

相似文献

Recent successes of cancer immunotherapy: a new dimension in personalized medicine?

Target Oncol. 2012 Mar;7(1):1-2. doi: 10.1007/s11523-012-0211-3. Epub 2012 Feb 15.

Cancer neoantigen: Boosting immunotherapy.癌症新生抗原：增强免疫疗法。

Biomed Pharmacother. 2020 Nov;131:110640. doi: 10.1016/j.biopha.2020.110640. Epub 2020 Aug 21.

From personalized to precision cancer medicine.从个性化癌症医学到精准癌症医学。

Per Med. 2020 Jul 1;17(4):245-250. doi: 10.2217/pme-2020-0056. Epub 2020 Jun 26.

Cancer Precision Medicine: From Cancer Screening to Drug Selection and Personalized Immunotherapy.癌症精准医学：从癌症筛查到药物选择和个性化免疫治疗。

Trends Pharmacol Sci. 2017 Jan;38(1):15-24. doi: 10.1016/j.tips.2016.10.013. Epub 2016 Nov 12.

Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy.迈向免疫检查点抑制剂和个体化癌症免疫治疗的时代。

Immunol Med. 2021 Mar;44(1):10-15. doi: 10.1080/25785826.2020.1785654. Epub 2020 Jul 9.

Personalized cancer care is not new.个体化癌症治疗并非新概念。

Oncologist. 2013 Jun;18(6):644-5. doi: 10.1634/theoncologist.2013-0203.

Personalized cancer medicine: next steps in the genomic era.个性化癌症医学：基因组时代的下一步进展

Cell Oncol (Dordr). 2015 Feb;38(1):1-2. doi: 10.1007/s13402-015-0221-0. Epub 2015 Feb 27.

Mutation-Derived Tumor Antigens: Novel Targets in Cancer Immunotherapy.突变衍生的肿瘤抗原：癌症免疫治疗中的新靶点。

Oncology (Williston Park). 2015 Dec;29(12):970-2, 974-5.

[Hot topics in 2017 in oncology and hematology. A selection by the editorial board of Bulletin du Cancer].[2017年肿瘤学与血液学热点话题。由《癌症通报》编辑委员会选编]

Bull Cancer. 2018 Jan;105(1):6-14. doi: 10.1016/j.bulcan.2017.11.006.

Therapeutic cancer vaccines: From initial findings to prospects.治疗性癌症疫苗：从初步发现到展望。

Immunol Lett. 2018 Apr;196:11-21. doi: 10.1016/j.imlet.2018.01.011. Epub 2018 Feb 4.

引用本文的文献

Improving lung cancer survival; time to move on.提高肺癌生存率；是时候采取行动了。

BMC Pulm Med. 2012 Dec 13;12:77. doi: 10.1186/1471-2466-12-77.

Molecular mimics of the tumour antigen MUC1.肿瘤抗原 MUC1 的分子模拟物。

PLoS One. 2012;7(11):e49728. doi: 10.1371/journal.pone.0049728. Epub 2012 Nov 14.

本文引用的文献

Targeting pattern recognition receptors in cancer immunotherapy.靶向肿瘤免疫治疗中的模式识别受体。

Target Oncol. 2012 Mar;7(1):29-54. doi: 10.1007/s11523-012-0213-1. Epub 2012 Mar 8.

Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival.白细胞介素-7 与癌症患者的免疫重建：大幅提高总体生存率的新模式。

Target Oncol. 2012 Mar;7(1):55-68. doi: 10.1007/s11523-012-0210-4. Epub 2012 Mar 2.

Adoptive transfer with high-affinity TCR to treat human solid tumors: how to improve the feasibility?采用高亲和力 TCR 进行过继转移治疗人类实体瘤：如何提高可行性？

Target Oncol. 2012 Mar;7(1):3-14. doi: 10.1007/s11523-012-0207-z. Epub 2012 Feb 15.

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps.具有生存获益的新型癌症免疫治疗药物：近期的成功和下一步措施。

Nat Rev Cancer. 2011 Oct 24;11(11):805-12. doi: 10.1038/nrc3153.

Cancer immunology--analysis of host and tumor factors for personalized medicine.癌症免疫学——用于个性化医疗的宿主和肿瘤因素分析。

Nat Rev Clin Oncol. 2011 Aug 9;8(12):711-9. doi: 10.1038/nrclinonc.2011.122.

Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.细胞转移免疫疗法治疗转移性实体瘤——临床医生需要了解的知识。

Nat Rev Clin Oncol. 2011 Aug 2;8(10):577-85. doi: 10.1038/nrclinonc.2011.116.

Cancer immunotherapy--revisited.癌症免疫疗法——再探。

Nat Rev Drug Discov. 2011 Aug 1;10(8):591-600. doi: 10.1038/nrd3500.

Immune parameters affecting the efficacy of chemotherapeutic regimens.影响化疗方案疗效的免疫参数。

Nat Rev Clin Oncol. 2011 Mar;8(3):151-60. doi: 10.1038/nrclinonc.2010.223.

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.基于痘病毒的 PSA 靶向免疫治疗转移性去势抵抗性前列腺癌的 II 期随机对照试验的总生存分析。

J Clin Oncol. 2010 Mar 1;28(7):1099-105. doi: 10.1200/JCO.2009.25.0597. Epub 2010 Jan 25.

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines.通过合成长肽疫苗对已确诊的（癌）前疾病进行免疫治疗。

Nat Rev Cancer. 2008 May;8(5):351-60. doi: 10.1038/nrc2373.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验